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ABSTRACT 
Introduction: Multiple factors negatively affect the quality of life of patients infected 
with hepatitis C virus. This study aims to evaluate the effect of pharmacological treatment on 
the quality of life of these individuals. Methods: This is a cross-sectional study conducted in 
two Southern Brazilian centers that used two instruments (a generic and a specific one) for 
measuring the quality of life in patients with chronic hepatitis C: the Short Form-36 (SF-36); 
and the Chronic Liver Disease Questionnaire (CLDQ) for liver disease. We included patients 
from two centers without any treatment (control group), or receiving medication (peginterferon 
+ ribavirin ± telaprevir or boceprevir, i.e., respectively, dual, and triple therapies). Results: 
One hundred and forty-seven patients were included. Patients under treatment (n = 86) had 
a lower score in 7 of the 8 SF-36 domains, with statistical significance (p<0.05) only for the 
emotional function domain. Patients who were not treated (n = 58) had higher scores in 4 of 
the 6 (p<0.05) CLDQ domains. A comparison of patients, receiving dual or triple therapies 
for both questionnaires, was only significant in the Vitality domain from CLDQ. Conclusions: 
Treatment can affect the subjective perception of patients regarding quality of life. Due to 
the complexity of the disease, each patient must be evaluated in multiple dimensions. Thus, 
the results may be useful for understanding the patient’s perceptions during treatment, and 
it can also serve as a reference for care instructions.
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INTRODUCTION
Due to its high morbidity rate, chronic hepatitis C currently constitutes a major 
public health problem. Hepatitis C is considered the most common cause of liver 
transplantation, with a mortality rate of 399,000 deaths per year. Currently, 71 million 
people are chronically infected with the hepatitis C virus (HCV), and are at risk for 
developing cirrhosis or hepatocarcinoma (HCC)1. Hepatitis C is not only restricted 
to the liver; it may also be considered a mental, psychological, family, and social 
disease because several factors negatively affect the patients’ quality of life. Adverse 
reactions to pharmacological treatment is also a burden for the patient, and along 
with the social stigmatization, may trigger serious social and familial isolation2-6. 
For many years, the treatment of chronic hepatitis C was based on the use 
of interferon, which could be used in combination with ribavirin and/or one 
of the first direct-acting antivirals (DAA), i.e., boceprevir and telaprevir. The 
combination of these drugs, in dual or triple therapies, made possible to increase 
the sustained virological response (SVR), defined as undetectable HCV RNA 
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after completion of antiviral therapy, compared to previous 
therapies. However, these treatments can be problematic 
due to the high incidence of adverse events, which can 
lead to treatment discontinuation, and still have limited 
efficacy, especially compared to a second generation of 
DAA that has been developed in recent years, and can 
be combined in therapies without IFN (which are called 
interferon-free therapies). 
The suffering caused by a disease is not limited only 
by pain or other discomforts, but also by the negative 
effects on patients’ daily lives and their ability to work 
and develop social relationships. Thus, studies related to 
quality of life increase the knowledge on the impact of 
the disease on daily activities, help in the identification of 
individual problems for each disease, and in the evaluation 
of treatments and patient adherence, as well as in obtaining 
essential information to allow the comparison of different 
treatments7-10.
Thus, in order to capture the patients’ perspectives 
during individual and collective health status assessments, 
quality of life questionnaires are commonly used. These 
can be general, specific, or modular11,12. The generic 
questionnaires (e.g., Short Form 36 - SF-36) cover an 
overview of the psychological and social status and also the 
physical and occupational functions, being used to evaluate 
a variety of health states and a wide range of diseases13,14. 
Specific questionnaires are applied to specific populations 
with particular diseases or treatment consequences, such 
as hepatitis C (e.g., Chronic Liver Disease Questionnaire 
- CLDQ). Finally, modular questionnaires involve a 
compound of both, generic and specific issues15-17. 
In recent years, studies about the evaluation of the 
quality of life, especially in chronic diseases, have 
occurred more frequently and attracted the attention of 
both researchers and political managers. Thus, the present 
study aimed to evaluate the effect of antiviral treatment on 
the quality of life of patients with CHC through SF-36 and 
CLDQ questionnaires.
METHODS
Study design
This is a cross-sectional study that was conducted 
from April 2014 to March 2015. Questionnaires were 
used to interview patients with CHC, who were under 
pharmacological treatment or not (control group), in two 
major medical care centers in the city of Curitiba, State of 
Paraná (the Clinical Hospital from Universidade Federal 
do Paraná [HC-UFPR] and the Guidance and Counseling 
Center of the City Health Department [COA-SMS]).
Study population and data collection
The study included patients with CHC, regardless of 
gender, who were above 18 years old. Patients were invited 
to participate in the study while awaiting routine medical 
consultation. As many patients as possible were interviewed 
from each center, and the number of patients that refused 
to participate was inexpressive. Those with a psychiatric 
diagnosis, women that were pregnant, and patients with 
hepatitis B virus (HBV) or human immunodeficiency virus 
(HIV) coinfections, were excluded from the study.
Patients from the HC-UFPR and COA-SMS were 
invited to participate and answer the questionnaires after 
signing the informed consent form. The Excel 2013 
software was used to assist in the collection and tabulation 
of collected data.
Measurement instruments
The researchers applied the SF-36 and the CLDQ 
questionnaires to assess the patients’ reported outcomes 
(PROs). The final structure of the SF-36 was the one 
developed by Ware and Sherbourne in 199218 and adapted 
for the Brazilian population by Ciconelli et al. in 199919, 
while the CLDQ was developed by Younossi et al.20 in 
1999 and adapted for the Brazilian population by Mucci 
et al.21 in 2010. 
The SF-36 consists of items (questions), scales (for each 
quality of life domain), and summary measures (physical 
and mental components). Altogether, there are 36 items 
divided into 8 domains22,23. Although it is not considered a 
specific domain, the sub-range of health transition intends 
to quantify the change in a patient’s overall health. The 
SF-36 domains are designated as follows: Physical Health 
(RL), Physical Functioning (PF), Pain (P) General Health 
(GH), Vitality (V), Social Functioning (SF), Emotional 
Well-Being (EW), and Mental Health (MH)24,25. Each 
scale is compounded by 2-10 items. These scales may 
be summarized through the two summary measures, the 
physical components (PCom = PF + RL + P + GH) and 
mental components (MCom = EW + V + SF + MH). Results 
are expressed as a score ranging from 0 to 100 for each 
of the eight scales, with higher scores indicating a better 
quality of life, or through the standardized score in the 
form of T-scores from the 2009 data for the US population 
(average of 50 and a standard deviation of 10), which has 
become much easier for the interpretation of results12,19,26.
The CLDQ consists of 29 items that are designed 
to measure the six domains of quality of life, including 
the abdominal symptoms (AS), fatigue (FA), systemic 
symptoms (SS), activity (AT), emotional function (EF), and 
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worry (WO). This questionnaire has two ways of presenting 
its scores, with one for each individual, and another for the 
general domains. Both scores range from 1 (worst) to 7 
(least severe), wherein higher scores indicate a minimum 
frequency of symptoms and, consequently, a better quality 
of life. The overall score is calculated by averaging the six 
dimensions20,21,27.
Statistical analysis 
Data were entered into an electronic spreadsheet in 
Excel and subsequently transferred and analyzed using the 
Minitab® 17. The Kolmogorov-Smirnov test was used to 
verify the distribution of parameters. As data distribution 
was not normal, non-parametric tests were applied in the 
comparative analysis.
The Mann-Whitney test was used for overall analysis 
and for four sub-analyses to verify possible statistical 
differences regarding four variables: gender (male versus 
female), marital status (Married/cohabiting versus single/
separated/widowed), comorbidities (yes versus no) and 
addictions (yes versus no). The four sub-analyses were 
made for the following groups: patients receiving treatment; 
patients without treatment; patients receiving IFN+RBV 
(duo therapy) and patients receiving one of the triple 
therapies. A p-value < 0.05 was considered significant and 
a α = 5% was adopted.
The study was approved by the Ethics Committee 
on Human Research of both institutions (approval Nº 
30486914.0.0000.0096 and 30486914.0.3001.0101 
respectively for HC-UFPR and COA-SMS), and is in 
accordance with the Helsinki Declaration of 1975.
RESULTS
The study included 147 patients (51% were female) 
with a median of 53 ± 10.9 years. Most individuals had 
a primary level of education (55.1%), 54.4% were either 
married or cohabiting, 73.5% did not report any kind of 
addiction, and the average monthly income of the group 
was U$ 475. The majority of the patients (73.5%) had 
undergone the genotyping test according to their medical 
records, and of these patients genotype 1 was predominant 
(67%). Table 1 presents all the sociodemographic data, and 
patients were divided into two groups: receiving treatment 
or not receiveing treatment.
Among all the patients, 58 (39.5%) were receiving 
treatment for CHC. Most of them (69%) received dual 
therapy (IFNpeg associated with Ribavirin) and the 
remaining patients received dual therapy combined with 
one of the first generation DAA, i.e., a triple therapy 
(IFNpeg/Ribavirin + telaprevir [13.8%] or boceprevir 
[17.2%]). Only one patient received telaprevir and IFNpeg 
without ribavirin (Table 1). 
Among the 147 included patients, three patients 
presented SF-36 scales with scores below 50 (PF, V and 
EW). Patients who were receiving treatment had lower 
scores on 7 domains, which was statistically significant 
(p<0.05) only for the EW domain. Regarding the CLDQ 
score, patients without antiviral treatment presented a 
significantly higher overall average (5.39 [1.15]). These 
patients also presented with significantly higher averages 
(p<0.05) in 4 of the 6 areas of CLDQ (FA, SS, AT, and 
EF) (Table 2). 
Another analysis was performed to compare domains 
SF-36 and CLDQ between patients receiving RBV/INFpeg 
(dual therapy) and triple therapies (BOC or TVR with 
RBV/INFpeg) and a significant statistical difference was 
observed only in Vitality domain from CLDQ (p<0.05).
Four different sub-analyses (Mann-Whitney test) were 
conducted (i.e., patients receiving treatment; patients 
without treatment; patients receiving IFN+RBV; and 
patients receiving one of the triple therapies), to analyze if 
there were statistical differences considering four variables: 
gender (male versus female), marital status (Married/
cohabiting versus single/separated/widowed), comorbidities 
(yes versus no) and additions (yes versus no). Full data from 
these analyses are presented in Table 3. 
DISCUSSION
Viral hepatitis constitutes a major public health problem. 
Among them, hepatitis C is considered the most common 
cause of liver transplantation, especially due to a slowly 
progressive disease and a high rate of chronicity, which 
makes it potentially fatal compared to the other types of 
viral hepatitis.
This study evaluated the effects of antiviral treatment 
on the subjective perception of the quality of life in patients 
with CHC. The overall analysis of the SF-36 questionnaire 
showed a statistically significant difference only in the 
emotional aspect domain, while CLDQ questionnaire had 
differences in some domains28. 
Several factors may contribute to the decrease of patients’ 
quality of life in hepatitis C patients, including natural 
manifestations of the disease such as fatigue, myalgia, 
nausea, vomiting, abdominal pain, and mental health 
problems. These symptoms may also be complications 
of the antiviral therapy. Adverse reactions of some drugs, 
such as pegylated interferon, ribavirin, and even protease 
inhibitors like telaprevir (fever, irritability, rash, itching, 
and diarrhea) are also contributing factors.
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The impact of treatment on the patient’s perception 
of quality of life is very useful, as seen in the numerous 
medications for CHC control that have been developed in 
recent years. Although triple therapy promotes higher SVR 
rates than dual therapy, our study did not show considerable 
differences in the quality of life between the two treatments. 
This could be due to the fact that peginterferon was still 
being used, which is related to an elevated number of side 
effects and a higher number of injections, which are thus 
expected to reduce the quality of life in chronic hepatitis 
C patients29-31. 
Three second generation DAA are being used in Brazil 
since 2015 (i.e., sofosbuvir, daclatasvir and simeprevir)32. 
They are oral drugs related to higher efficacy rates and a 
better safety profile, which may increase the quality of life 
of these patients and also of work productivity. This could 
be associated to the fact that oral antiviral treatment is 
correlated with a higher quality of life, promotes less side 
Table 1 - Comparison of the sociodemographic and clinical categorical variables of the study population
PARAMETER
Total Patients 
N (147)
Patients with 
medication 
N (58)
Patients without 
medication 
N (89)
p-value
GENDER Male 72 (49%) 31 (53.5%) 41 (46%) 0.382
GENOTYPE 0.128
1 (Unspecified) 
1a 
1b 
1a e 1b 
2 
3 
4 
Not informed
21 (14%) 
25 (17%) 
26 (17.7%) 
1 (0.7%) 
2 (1.4%) 
33 (22.4%) 
1 (0.7%) 
39 (26.5%)
11 (29%) 
14 (24%) 
14 (24%) 
1 (1.7%) 
1 (1.7%) 
9 (15.5%) 
0  
8 (13.8%)
9 (10%) 
11 (12.3%) 
12 (13.4%) 
0  
1 (1.1%) 
24 (27%) 
1 (1.1%) 
31 (34.8%)
RACE 0.183
White 
Black 
Brown
129 (87%) 
14 (9.5%) 
4 (2.7%)
52 (89.6%) 
6 (10%) 
0 
77 (86.5%) 
8 (9%) 
4 (4.5%)
MARITAL STATUS 0.244
Married or cohabiting 
Single/separated/
widowed
80 (54.4%) 
67 (45.6%)
35 (60%) 
23 (39%)
45 (50.5%) 
44 (49.4%)
EDUCATIONAL LEVEL 0.127
Illiterate 
Elementary School 
Secondary School 
Technical Degree 
High School
1 (0.7%) 
81 (55.1%) 
42 (28.6%) 
2 (1.4%) 
21 (14.3%)
1 (1.7%) 
29 (50%) 
22 (38%) 
1 (1.7%) 
5 (8.2%)
0 
52 (58.4%) 
20 (22.5%) 
1 (1.1%) 
16 (18%)
COMORBIDITIES 0.807
Yes 
No
92 (62.6%) 
55 (37.4%)
37 (63.7%) 
21 (36%)
55 (61.8%) 
34 (38.2%)
TREATMENT IFNpeg/RBV 
IFNpeg/TVR 
IFNpeg/RBV/TVR 
IFNpeg/RBV/BOC 
None
40 (27.2%) 
1 (0.7%) 
10 (6.8%) 
7 (4.7%) 
89 (60.5%)
40 (69%)  
1 (1.7) 
10 (17.2) 
7 (12) 
0
0 
0 
0 
0 
89 (100%)
ADDICTIONS 0.815
Yes 
No
39 (26.5%) 
108 (73.5%)
16 (27.5%) 
42 (72.4%)
23 (25.8%) 
66 (74.1%)
METAVIR 0.142
F0 
F1 
F2 
F3 
F4 
Not informed
2 (1.4%) 
2 (1.4%) 
8 (5.4%) 
11 (7.5%) 
9 (6.1%) 
115 (78.2%)
0 
1 (1.7%) 
6 (10.3%) 
8 (13.8%) 
3 (5.1%) 
40 (69%)
2 (2.2%) 
1 (1.1%) 
2 (2.2%) 
3 (3.3%) 
6 (6.7%) 
75 (84.2%)
*significant. IFNpeg= Pegylated Interferon; RBV= Ribavirin; TVR= Telaprevir; BOC= Boceprevir. F0= no fibrosis; F1= mild fibrosis; 
F2= moderate fibrosis; F3= severe fibrosis; F4= cirrhosis.
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effects and have lower treatment duration33-38.
It is evident that most patients are asymptomatic 
during the natural course of the disease. However, the 
peak of viral prevalence occurs among individuals who 
are in the fifth decade of life; adult subjects who are in the 
active phase of life. In this phase, it appears that hepatic 
cirrhosis is the most common symptom in 20 to 30% of 
patients with chronic infections. Subsequently, cirrhosis 
and hepatocellular carcinoma often develop in 1 to 4% of 
patients per year39-41.
Table 2 - Comparison of the SF-36 and CLDQ scores between patients with or without current treatment
Domains of SF-36 and CLDQ
Patients receiving 
treatment (N=86), 
Mean (SD)
Patients without any 
treatment (N=58), 
Mean (SD)
p-value
SF-36
RL 74.10 (±26.94) 68.96 (±26.65) 0.188
PF 58.15 (±45.19) 46.98 (±43.95) 0.102
P 60.92 (±31.23) 54.33 (±32.95) 0.243
GH 67.65 (±25.25) 67.71 (±22.33) 0.838
V 58.71 (±30.44) 48.44 (±32.07) 0.057
SF 75.56 (±28.07) 70.26 (±29.88) 0.335
EW 62.14 (±46.92) 46.78 (±44.92) 0.037*
MH 63.73 (±27.68) 59.46 (±29.39) 0.433
PCom 52.63 (±7.72) 53.65 (±7.99) 0.376
MCom 54.10 (±14.46) 57.51 (±14.84) 0.162
CLDQ
AS 5.45 (1.59) 5.37 (1.76) 0.351
FA 4.82 (1.78) 3.96 (1.71) 0.004*
SS 5.44 (1.37) 4.54 (1.38) 0.000*
AT 5.87 (1.24) 4.82 (1.48) 0.000*
EF 5.15 (1.40) 4.64 (1.34) 0.010*
WO 5.59 (1.38) 5.13 (1.71) 0.148
Overall score 5.39 (1.15) 4.74 (1.01) 0.000*
*p<0.05; Abbreviations: RL, Role Limitations due to Physical Health; PF, Physical Functioning; P, Pain; GH, General Health; V, Vitality; 
SF, Social Functioning; EW, Emotional Well-Being; MH, Mental Health; PCom, Physical Component; MCom, Mental Component; 
AS, Abdominal Symptoms; FA, Fatigue; SS, Systemic Symptoms; AT, Activity; EF, Emotional Function; WO, Worry.
Table 3 - Results of the Mann-Whitney test relating variables (gender, marital status, comorbidities and addictions) to the fact that 
patients received treatment or did not
Group of patients 
evaluated in MW test
Variable
Gender Marital status Comorbidities Addictions
(a) MW test including 
patients receiving any 
treatment
SF-36 (PF, RL, P, GH and 
Pcom) and CLDQ (AS, 
SS, AT and overall score)
- SF-36 (RL, P, SF, EW, 
Mcom) and CLDQ (AS, 
AT and overall scores)
CLDQ (AS)
(b) MW test inclunding 
patients without 
treatment
SF-36 (RL) - SF-36 (RL and Mcom) SF-36 (P, EW, V, MH, 
Mcom) and CLDQ (SS)
(c) MW test for patients 
that were treated with 
duo therapy
SF-36 (RL, Pcom) and 
CLDQ (AS, SS, AC, 
overall scores)
CLDQ (FA) CLDQ (AS, SS and 
overall scores)
CLDQ (AS and EF)
(d) MW test for patients 
that were treated with 
triple therapy
SF-36 (P) SF-36 (GH) SF-36 (RL,SF, EW,MH 
and Mcom)
-
Note: This table presents the statistical significant results from the sub analysis according to each variable using Mann-Whitney test 
(i.e. male vs female; Married/cohabiting vs. single/separated/widowed; comorbidities yes vs. no; and additions yes vs. no). Each line 
indicate a different group of patients: (a) patient without treatment, (b) patients receiving treatment, (c) patient receiving duo therapy, 
(d) patients receiving triple therapy. For example the variable gender, the mean score from each domain was compared between 
male and female patients. The table present only the domains that were statistical significant (in parentheses) from the respective 
questionnaire, which in the specific case of the patients receinving triple therapy was observed only in the pain (P) domain of SF-36.
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Some authors point out that in addition to treatment, 
other factors can also influence the quality of life such as 
ethnicity, income, work, and educational level42. However, 
others declare that factors such as age, genotype, degree 
of fibrosis, do not seem to exert any effect on the quality 
of life24.
Despite the adaptation to the local reality where the study 
was conducted, the small sample size in some groups and 
the absence of additional control groups were considered 
limitations. To generalize the results, it is necessary to 
replicate this study in more States in Brazil. Additionally, 
other social economical aspects (such as monthly income 
and educational level), laboratory data (e.g., albumin, 
bilirubin, alanine and aspartate aminotransferase) and the 
time since the diagnosis (the stage of the disease) were not 
evaluated here. This last parameter could not be analyzed 
especially due to missing data. As the second generation 
DAA was not evaluated in this study, we suggest the 
evaluation of quality of life of hepatitis C patients receiving 
these drugs in Brazil.
CONCLUSIONS
This study showed that, in some domains, there is a 
decrease in the quality of life in treated patients with CHC 
receiving interferon-based therapies, which is associated 
with a significant number of side effects and injections. 
Additionally, the quality of life was similar in patients 
receiving dual and triple therapies with first-generation 
DAAs. The data found in this study provided a better 
understanding of the quality of life of patients with hepatitis 
C and their needs, which will ensure better healthcare for 
those who are undergoing treatment.
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